The Lancet Oncology, Volume 9, Issue 10 , Pages 908 - 909,
October 2008 doi:10.1016/S1470-2045(08)70211-0Cite or Link Using
DOI A global approach to cancer-screening trials In all aspects
of medicine and public health, the gold standard to measure the
efficacy of a new intervention is a prospective randomised
controlled trial (RCT). Each year, many RCTs are launched to
assess new cancer therapies, but RCTs to assess population-based
strategies for prevention or early detection are rare, even
though their findings might have far greater potential to
benefit the public's health. The main reason for this disparity
is the enormous cost of these investigations. Assessme ... This
article is made available free of charge, as a service to our
users. Please login to access the full article, or register if
you do not yet have a username and password. Already Registered?
Please Login New to TheLancet.com? TheLancet.com is the online
home of: - The Lancet - The Lancet Diabetes & Endocrinology -
The Lancet Infectious Dise